Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. CDN Services

We are analyzing https://link.springer.com/article/10.1007/s10549-008-0251-7.

Title:
A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab | Breast Cancer Research and Treatment
Description:
Trastuzumab mediates the lysis of HER2-expressing breast cancer cell lines by interleukin-2 (IL-2) primed natural killer (NK) cells. We hypothesized that IL-2 would augment the anti-tumor effects of trastuzumab in MBC in patients who had progressed on or within 12 months of receiving a trastuzumab-containing regimen. Secondary objectives were to measure antibody-directed cellular cytotoxicity (ADCC) against HER2 over-expressing target cells, and to measure serum cytokines. Patients received trastuzumab (4 mg/kg intravenously (IV)) every 2 weeks in combination with daily low-dose IL-2 (1 million IU/m2 subcutaneously (SC)) and pulsed intermediate-dose IL-2 (12 million IU/m2 SC). Samples were analyzed for NK cell expansion and ADCC against a HER2-positive breast cancer cell line. In addition, interferon-gamma (IFN-γ), mRNA expression in peripheral blood mononuclear cells (PBMC) and the following serum cytokines were measured: IFN-γ, monokine-induced by IFN-γ (MIG), and interferon-inducible protein ten (IP-10). The median number of treatment cycles was four (range 1–23) and the treatment was well tolerated. There were no objective responses. NK cells were not expanded and ADCC was not enhanced. Eight (62%) patients had a twofold or higher increase in mRNA transcript for IFN-γ, two (15%) patients had elevated serum levels of IFN-γ and 12 (92%) had increases angiogenic MIG and IP-10. In trastuzumab-refractory patients adding IL-2 did not produce responses and did not result in NK cell expansion. However, these patients had the ability to respond to IL-2 as evidenced by increases in IFN-γ transcripts and chemokines. The lack of NK cell expansion may explain the absence of clinical benefit.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

  • Health & Fitness
  • Science
  • Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't figure out the monetization strategy.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

cancer, article, google, scholar, pubmed, cas, breast, cells, trastuzumab, patients, interleukin, cell, killer, res, carson, natural, clin, usa, university, treatment, phase, clinical, research, trial, combination, roda, caligiuri, ifnγ, access, parihar, response, doiccr, state, privacy, cookies, content, young, iii, human, tumor, van, ohio, columbus, publish, search, metastatic, mani, fleming, shapiro, cellular,

Topics {✒️}

month download article/chapter lymphokine-activated killer cells antibody-dependent cellular cytotoxicity her2-positive breast cancer her2-expressing breast cancer antibody-coated tumor cells ab-coated tumor cells 1 million iu/m2 subcutaneously nih/nci grants p30 interferon-inducible protein ten her2-specific cytotoxic activity neoadjuvant anti-her2 antibodies 12 million iu/m2 sc breast cancer cells natural killer cells nk cell expansion pulsed intermediate-dose il-2 ohio state university human breast cancer daily low-dose il-2 expressing target cells metastatic breast cancer full article pdf primed natural killer related subjects breast cancer targets previously failed trastuzumab privacy choices/manage cookies antibody-coated targets adam brufsky b-cell nk cells anti-tumor effects low-dose interleukin-2 national cancer institute adoptive immunotherapy van krieken jh cell-recruiting chemokines vitro cytotoxic effect combination immunotherapy intrinsic drug resistance amy stark ms nrsa t32 fellow phase ii trial her2/neu de vries ij de wilde pc de mulder ph article mani dendritic cells

Questions {❓}

  • Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V, Bertheau P, Garnier J, Jeannin JF, Coudert B (2006) Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab
         description:Trastuzumab mediates the lysis of HER2-expressing breast cancer cell lines by interleukin-2 (IL-2) primed natural killer (NK) cells. We hypothesized that IL-2 would augment the anti-tumor effects of trastuzumab in MBC in patients who had progressed on or within 12 months of receiving a trastuzumab-containing regimen. Secondary objectives were to measure antibody-directed cellular cytotoxicity (ADCC) against HER2 over-expressing target cells, and to measure serum cytokines. Patients received trastuzumab (4 mg/kg intravenously (IV)) every 2 weeks in combination with daily low-dose IL-2 (1 million IU/m2 subcutaneously (SC)) and pulsed intermediate-dose IL-2 (12 million IU/m2 SC). Samples were analyzed for NK cell expansion and ADCC against a HER2-positive breast cancer cell line. In addition, interferon-gamma (IFN-γ), mRNA expression in peripheral blood mononuclear cells (PBMC) and the following serum cytokines were measured: IFN-γ, monokine-induced by IFN-γ (MIG), and interferon-inducible protein ten (IP-10). The median number of treatment cycles was four (range 1–23) and the treatment was well tolerated. There were no objective responses. NK cells were not expanded and ADCC was not enhanced. Eight (62%) patients had a twofold or higher increase in mRNA transcript for IFN-γ, two (15%) patients had elevated serum levels of IFN-γ and 12 (92%) had increases angiogenic MIG and IP-10. In trastuzumab-refractory patients adding IL-2 did not produce responses and did not result in NK cell expansion. However, these patients had the ability to respond to IL-2 as evidenced by increases in IFN-γ transcripts and chemokines. The lack of NK cell expansion may explain the absence of clinical benefit.
         datePublished:2008-12-03T00:00:00Z
         dateModified:2008-12-03T00:00:00Z
         pageStart:83
         pageEnd:89
         sameAs:https://doi.org/10.1007/s10549-008-0251-7
         keywords:
            Trastuzumab
            Her-2/neu
            Interleukin-2
            Breast cancer
            Clinical trial
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-008-0251-7/MediaObjects/10549_2008_251_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-008-0251-7/MediaObjects/10549_2008_251_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-008-0251-7/MediaObjects/10549_2008_251_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-008-0251-7/MediaObjects/10549_2008_251_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-008-0251-7/MediaObjects/10549_2008_251_Fig5_HTML.gif
         isPartOf:
            name:Breast Cancer Research and Treatment
            issn:
               1573-7217
               0167-6806
            volumeNumber:117
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Aruna Mani
               affiliation:
                     name:Ohio State University Medical Center
                     address:
                        name:Division of Hematology and Oncology, Department of Internal Medicine, Ohio State University Medical Center, Columbus, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Julie Roda
               affiliation:
                     name:Ohio State University
                     address:
                        name:Integrated Biomedical Sciences Graduate Program, Department of Molecular Virology, Ohio State University, Columbus, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Donn Young
               affiliation:
                     name:Ohio State University
                     address:
                        name:Department of Biostatistics, Ohio State University, Columbus, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Michael A. Caligiuri
               affiliation:
                     name:Ohio State University Medical Center
                     address:
                        name:Division of Hematology and Oncology, Department of Internal Medicine, Ohio State University Medical Center, Columbus, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Gini F. Fleming
               affiliation:
                     name:University of Chicago
                     address:
                        name:University of Chicago, Chicago, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Peter Kaufman
               affiliation:
                     name:Dartmouth University
                     address:
                        name:Dartmouth University, Hanover, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Adam Brufsky
               affiliation:
                     name:University of Pittsburgh
                     address:
                        name:University of Pittsburgh, Pittsburgh, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Susan Ottman
               affiliation:
                     name:Ohio State University Comprehensive Cancer Center
                     address:
                        name:Ohio State University Comprehensive Cancer Center, Columbus, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:William E. Carson
               affiliation:
                     name:Ohio State University
                     address:
                        name:Division of Surgical Oncology, Department of Surgery, Ohio State University, Columbus, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Charles L. Shapiro
               affiliation:
                     name:Ohio State University Medical Center
                     address:
                        name:Division of Hematology and Oncology, Department of Internal Medicine, Ohio State University Medical Center, Columbus, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab
      description:Trastuzumab mediates the lysis of HER2-expressing breast cancer cell lines by interleukin-2 (IL-2) primed natural killer (NK) cells. We hypothesized that IL-2 would augment the anti-tumor effects of trastuzumab in MBC in patients who had progressed on or within 12 months of receiving a trastuzumab-containing regimen. Secondary objectives were to measure antibody-directed cellular cytotoxicity (ADCC) against HER2 over-expressing target cells, and to measure serum cytokines. Patients received trastuzumab (4 mg/kg intravenously (IV)) every 2 weeks in combination with daily low-dose IL-2 (1 million IU/m2 subcutaneously (SC)) and pulsed intermediate-dose IL-2 (12 million IU/m2 SC). Samples were analyzed for NK cell expansion and ADCC against a HER2-positive breast cancer cell line. In addition, interferon-gamma (IFN-γ), mRNA expression in peripheral blood mononuclear cells (PBMC) and the following serum cytokines were measured: IFN-γ, monokine-induced by IFN-γ (MIG), and interferon-inducible protein ten (IP-10). The median number of treatment cycles was four (range 1–23) and the treatment was well tolerated. There were no objective responses. NK cells were not expanded and ADCC was not enhanced. Eight (62%) patients had a twofold or higher increase in mRNA transcript for IFN-γ, two (15%) patients had elevated serum levels of IFN-γ and 12 (92%) had increases angiogenic MIG and IP-10. In trastuzumab-refractory patients adding IL-2 did not produce responses and did not result in NK cell expansion. However, these patients had the ability to respond to IL-2 as evidenced by increases in IFN-γ transcripts and chemokines. The lack of NK cell expansion may explain the absence of clinical benefit.
      datePublished:2008-12-03T00:00:00Z
      dateModified:2008-12-03T00:00:00Z
      pageStart:83
      pageEnd:89
      sameAs:https://doi.org/10.1007/s10549-008-0251-7
      keywords:
         Trastuzumab
         Her-2/neu
         Interleukin-2
         Breast cancer
         Clinical trial
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-008-0251-7/MediaObjects/10549_2008_251_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-008-0251-7/MediaObjects/10549_2008_251_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-008-0251-7/MediaObjects/10549_2008_251_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-008-0251-7/MediaObjects/10549_2008_251_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-008-0251-7/MediaObjects/10549_2008_251_Fig5_HTML.gif
      isPartOf:
         name:Breast Cancer Research and Treatment
         issn:
            1573-7217
            0167-6806
         volumeNumber:117
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Aruna Mani
            affiliation:
                  name:Ohio State University Medical Center
                  address:
                     name:Division of Hematology and Oncology, Department of Internal Medicine, Ohio State University Medical Center, Columbus, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Julie Roda
            affiliation:
                  name:Ohio State University
                  address:
                     name:Integrated Biomedical Sciences Graduate Program, Department of Molecular Virology, Ohio State University, Columbus, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Donn Young
            affiliation:
                  name:Ohio State University
                  address:
                     name:Department of Biostatistics, Ohio State University, Columbus, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Michael A. Caligiuri
            affiliation:
                  name:Ohio State University Medical Center
                  address:
                     name:Division of Hematology and Oncology, Department of Internal Medicine, Ohio State University Medical Center, Columbus, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Gini F. Fleming
            affiliation:
                  name:University of Chicago
                  address:
                     name:University of Chicago, Chicago, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Peter Kaufman
            affiliation:
                  name:Dartmouth University
                  address:
                     name:Dartmouth University, Hanover, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Adam Brufsky
            affiliation:
                  name:University of Pittsburgh
                  address:
                     name:University of Pittsburgh, Pittsburgh, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Susan Ottman
            affiliation:
                  name:Ohio State University Comprehensive Cancer Center
                  address:
                     name:Ohio State University Comprehensive Cancer Center, Columbus, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:William E. Carson
            affiliation:
                  name:Ohio State University
                  address:
                     name:Division of Surgical Oncology, Department of Surgery, Ohio State University, Columbus, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Charles L. Shapiro
            affiliation:
                  name:Ohio State University Medical Center
                  address:
                     name:Division of Hematology and Oncology, Department of Internal Medicine, Ohio State University Medical Center, Columbus, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research and Treatment
      issn:
         1573-7217
         0167-6806
      volumeNumber:117
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Ohio State University Medical Center
      address:
         name:Division of Hematology and Oncology, Department of Internal Medicine, Ohio State University Medical Center, Columbus, USA
         type:PostalAddress
      name:Ohio State University
      address:
         name:Integrated Biomedical Sciences Graduate Program, Department of Molecular Virology, Ohio State University, Columbus, USA
         type:PostalAddress
      name:Ohio State University
      address:
         name:Department of Biostatistics, Ohio State University, Columbus, USA
         type:PostalAddress
      name:Ohio State University Medical Center
      address:
         name:Division of Hematology and Oncology, Department of Internal Medicine, Ohio State University Medical Center, Columbus, USA
         type:PostalAddress
      name:University of Chicago
      address:
         name:University of Chicago, Chicago, USA
         type:PostalAddress
      name:Dartmouth University
      address:
         name:Dartmouth University, Hanover, USA
         type:PostalAddress
      name:University of Pittsburgh
      address:
         name:University of Pittsburgh, Pittsburgh, USA
         type:PostalAddress
      name:Ohio State University Comprehensive Cancer Center
      address:
         name:Ohio State University Comprehensive Cancer Center, Columbus, USA
         type:PostalAddress
      name:Ohio State University
      address:
         name:Division of Surgical Oncology, Department of Surgery, Ohio State University, Columbus, USA
         type:PostalAddress
      name:Ohio State University Medical Center
      address:
         name:Division of Hematology and Oncology, Department of Internal Medicine, Ohio State University Medical Center, Columbus, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Aruna Mani
      affiliation:
            name:Ohio State University Medical Center
            address:
               name:Division of Hematology and Oncology, Department of Internal Medicine, Ohio State University Medical Center, Columbus, USA
               type:PostalAddress
            type:Organization
      name:Julie Roda
      affiliation:
            name:Ohio State University
            address:
               name:Integrated Biomedical Sciences Graduate Program, Department of Molecular Virology, Ohio State University, Columbus, USA
               type:PostalAddress
            type:Organization
      name:Donn Young
      affiliation:
            name:Ohio State University
            address:
               name:Department of Biostatistics, Ohio State University, Columbus, USA
               type:PostalAddress
            type:Organization
      name:Michael A. Caligiuri
      affiliation:
            name:Ohio State University Medical Center
            address:
               name:Division of Hematology and Oncology, Department of Internal Medicine, Ohio State University Medical Center, Columbus, USA
               type:PostalAddress
            type:Organization
      name:Gini F. Fleming
      affiliation:
            name:University of Chicago
            address:
               name:University of Chicago, Chicago, USA
               type:PostalAddress
            type:Organization
      name:Peter Kaufman
      affiliation:
            name:Dartmouth University
            address:
               name:Dartmouth University, Hanover, USA
               type:PostalAddress
            type:Organization
      name:Adam Brufsky
      affiliation:
            name:University of Pittsburgh
            address:
               name:University of Pittsburgh, Pittsburgh, USA
               type:PostalAddress
            type:Organization
      name:Susan Ottman
      affiliation:
            name:Ohio State University Comprehensive Cancer Center
            address:
               name:Ohio State University Comprehensive Cancer Center, Columbus, USA
               type:PostalAddress
            type:Organization
      name:William E. Carson
      affiliation:
            name:Ohio State University
            address:
               name:Division of Surgical Oncology, Department of Surgery, Ohio State University, Columbus, USA
               type:PostalAddress
            type:Organization
      name:Charles L. Shapiro
      affiliation:
            name:Ohio State University Medical Center
            address:
               name:Division of Hematology and Oncology, Department of Internal Medicine, Ohio State University Medical Center, Columbus, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Division of Hematology and Oncology, Department of Internal Medicine, Ohio State University Medical Center, Columbus, USA
      name:Integrated Biomedical Sciences Graduate Program, Department of Molecular Virology, Ohio State University, Columbus, USA
      name:Department of Biostatistics, Ohio State University, Columbus, USA
      name:Division of Hematology and Oncology, Department of Internal Medicine, Ohio State University Medical Center, Columbus, USA
      name:University of Chicago, Chicago, USA
      name:Dartmouth University, Hanover, USA
      name:University of Pittsburgh, Pittsburgh, USA
      name:Ohio State University Comprehensive Cancer Center, Columbus, USA
      name:Division of Surgical Oncology, Department of Surgery, Ohio State University, Columbus, USA
      name:Division of Hematology and Oncology, Department of Internal Medicine, Ohio State University Medical Center, Columbus, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(132)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

CDN Services {📦}

  • Crossref

4.41s.